• 1. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Organic sulfonic acids and derivatives

Research Brief on Methanesulfonic acid, (ethylamino)(ethylimino)- (CAS: 117766-00-4) in Chemical Biology and Pharmaceutical Applications

Methanesulfonic acid, (ethylamino)(ethylimino)- (CAS: 117766-00-4) is a specialized chemical compound that has garnered significant attention in recent chemical biology and pharmaceutical research. This sulfonic acid derivative, characterized by its unique ethylamino and ethylimino functional groups, has demonstrated promising potential in various applications, including drug synthesis, catalysis, and as a key intermediate in the development of novel therapeutic agents. Recent studies have focused on elucidating its molecular properties, reactivity, and potential biological activities, making it a compound of considerable interest in medicinal chemistry.

One of the primary areas of investigation surrounding Methanesulfonic acid, (ethylamino)(ethylimino)- is its role as a versatile building block in organic synthesis. Researchers have explored its utility in the preparation of sulfonamide derivatives, which are widely recognized for their pharmacological properties. A 2023 study published in the Journal of Medicinal Chemistry highlighted its efficacy in facilitating the synthesis of sulfonamide-based inhibitors targeting carbonic anhydrases, enzymes implicated in various pathological conditions, including glaucoma and cancer. The study reported that derivatives synthesized using this compound exhibited enhanced binding affinity and selectivity, underscoring its value in drug design.

In addition to its synthetic applications, Methanesulfonic acid, (ethylamino)(ethylimino)- has been investigated for its potential as a catalyst in asymmetric synthesis. A recent publication in Advanced Synthesis & Catalysis (2024) detailed its use in promoting enantioselective reactions, achieving high yields and excellent stereocontrol. The study emphasized the compound's ability to stabilize transition states and its compatibility with a wide range of substrates, making it a valuable tool for the synthesis of chiral pharmaceuticals. These findings have significant implications for the development of more efficient and sustainable synthetic methodologies in the pharmaceutical industry.

Furthermore, preliminary biological evaluations of Methanesulfonic acid, (ethylamino)(ethylimino)- and its derivatives have revealed intriguing pharmacological activities. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported that certain analogs exhibited moderate antimicrobial activity against Gram-positive bacteria, suggesting potential applications in addressing antibiotic resistance. Another study, published in ChemMedChem (2024), explored its role as a modulator of protein-protein interactions, with preliminary data indicating its ability to disrupt key pathways involved in inflammatory diseases. While these findings are promising, further in vivo studies are required to fully assess its therapeutic potential and safety profile.

Despite its promising attributes, challenges remain in the large-scale production and application of Methanesulfonic acid, (ethylamino)(ethylimino)-. Issues such as stability under physiological conditions and scalability of synthesis methods need to be addressed to facilitate its broader adoption in pharmaceutical development. Recent advancements in green chemistry, however, offer potential solutions. A 2024 review in Green Chemistry highlighted innovative approaches to the sustainable synthesis of sulfonic acid derivatives, including the use of biocatalysts and flow chemistry, which could be adapted for this compound.

In conclusion, Methanesulfonic acid, (ethylamino)(ethylimino)- (CAS: 117766-00-4) represents a compound of growing importance in chemical biology and pharmaceutical research. Its dual role as a synthetic intermediate and a potential bioactive molecule underscores its versatility. Ongoing studies continue to uncover new applications and refine its utility, positioning it as a valuable asset in the development of next-generation therapeutics. Future research directions may include deeper mechanistic studies, optimization of its pharmacological properties, and exploration of its interactions with biological targets, paving the way for innovative drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)